These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk? Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255 [TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
27. Clinical significance of fluid biomarkers in Alzheimer's Disease. Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624 [TBL] [Abstract][Full Text] [Related]
28. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration. Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250 [TBL] [Abstract][Full Text] [Related]
31. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455 [TBL] [Abstract][Full Text] [Related]
32. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Giedraitis V; Sundelöf J; Irizarry MC; Gårevik N; Hyman BT; Wahlund LO; Ingelsson M; Lannfelt L Neurosci Lett; 2007 Nov; 427(3):127-31. PubMed ID: 17936506 [TBL] [Abstract][Full Text] [Related]
33. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
34. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
35. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249 [TBL] [Abstract][Full Text] [Related]
36. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
37. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805 [TBL] [Abstract][Full Text] [Related]
38. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076 [TBL] [Abstract][Full Text] [Related]
39. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis. Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998 [TBL] [Abstract][Full Text] [Related]
40. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]